P1.101. Treatment Selection and Real-World Outcomes of First-Line ICI-Based Therapy for Unresectable or Recurrent Esophageal Cancer in a Regional Hospital
Clicks: 3
ID: 325724
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #218 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Management of Metastatic Cancer Background Based on pivotal clinical trials, immune checkpoint inhibitors (ICIs) have demonstrated efficacy in patients with unresectable advanced or recurrent esophageal cancer and are now incorporated as standard treatment in the Japanese clinical practice guidelines. Although expanded therapeutic options are expected to improve survival outcomes, real-world data remain limited. Our institution is a regional hospital where a large proportion of patients are elderly, and esophageal cancer treatment is mainly managed by surgeons. This study aimed to evaluate real-world treatment selection and outcomes of ICI-based therapies at our institution. Methods We retrospectively analyzed 28 consecutive patients with unresectable advanced or recurrent esophageal cancer who received first-line ICI combined with chemotherapy (ICI+C) or dual ICI therapy (IO+IO) between July 2022 and December 2025 at a regional core hospital. Patient demographics, disease status (unresectable vs. recurrent), prior treatment history, renal function, treatment cycles, immune-related adverse events (irAEs), response rates, subsequent therapy, and overall survival were evaluated. Treatment responses were assessed in patients with measurable lesions according to standard radiological criteria. Overall survival was calculated from treatment initiation to death or last follow-up. Clinical characteristics and outcomes were compared descriptively between the two treatment groups. Results Nine patients received ICI+C (median age 80 years), and nineteen received IO+IO (median age 71 years). ICI+C was more frequently selected for unresectable disease and elderly patients. All ICI+C patients received dose-reduced 5-fluorouracil plus cisplatin. The median number of cycles was 11 in the ICI+C group and 2 in the IO+IO group. irAEs occurred in 33% and 68% of patients, respectively. Among evaluable patients, best responses (CR/PR/SD/PD) were 1/3/1/1 in the ICI+C group and 2/6/1/3 in the IO+IO group. Second-line therapy was administered in 4 and 6 patients, respectively. Median overall survival was 994 days in the ICI+C group and 391 days in the IO+IO group. Conclusion At our regional institution, ICI+C was more frequently selected for elderly patients with unresectable disease and achieved favorable tumor control and prolonged survival. In contrast, IO+IO was more often administered in recurrent cases and was associated with a higher incidence of progressive disease and irAEs, resulting in fewer treatment cycles. Notably, durable responses with a tail plateau pattern were observed in both groups, suggesting a meaningful survival benefit associated with the addition of ICIs in real-world clinical practice.
| Reference Key |
openalex_W7203938148
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Tomonari Suetsugu, Narutoshi Nagao, Kazuo Yamamoto, Shinya Ohno, Shunya Kiriyama, Kakeru Tawada, Yoshinori Iwata, Chihiro Tanaka, Masahiko Kawai |
| Journal | diseases of the esophagus : official journal of the international society for diseases of the esophagus |
| Year | 2026 |
| DOI |
10.1093/dote/doag077.249
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.